INTRODUCTION Since the approval of Orthoclone OKT3, a murine monoclonal antibody against T cell expressed CD3 (for the treatment of acute transplant rejection) in 1986, antibody based pharmacological interventions have evolved into a prominent class of therapeutics.
New York, March 10, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Antibody Discovery Services and Platforms Market : Distribution by Type of Service Offered, Antibody Discovery Method, Nature of Antibody Generated and Key Geographies : Industry Trends and Global Forecasts, 2022-2035" – https://www.reportlinker.com/p06244063/?utm_source=GNW
These therapeutics have high target specificities and favorable safety profiles. Currently, close to 100 monoclonal antibodies have been approved while more than 500 molecules are being evaluated in clinical trials. Some of the recently approved monoclonal antibody therapies include (in reverse chronological order) Tivdak® (September 2021), Saphnelo® (August 2021), Rybrevant® (May 2021), Ebanga (December 2020) and MARGENZA® (December 2020). The growing popularity of antibody based therapeutics is also reflected from the extensive research being conducted on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments in the past few years.
It is worth highlighting that the process of antibody development, beginning from the discovery to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, antibody discovery and clinical research are capital intensive processes, which, on an average, require investments of around USD 4-10 billion. Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation during the discovery phase make it into the clinical phase, and an even lesser number of product candidates enter the market. In order to optimize on internal resource utilization and save costs, pharmaceutical companies are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs). Apart from being considered a viable business strategy, engaging third party service providers offers both time and cost related benefits to the drug / therapy developers. Given the rising demand for antibody based therapeutics and growing preference for outsourcing, we are led to believe that the opportunity for contract service provides and technology developers is likely to increase at a steady rate in the foreseen future.
SCOPE OF THE REPORT
The “Antibody Discovery Services and Platforms Market by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Library based, Hybridoma based, Single Cell based, Transgenic Animal based), Nature of Antibody Generated (Monoclonal, Bispecific, Antibody-Drug Conjugates, Antibody Fragments) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecast (4th Edition), 2021-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years. The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics. In addition to other elements, it includes:
An overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).
An insightful competitiveness analysis of antibody discovery service providers, based on supplier strength (based on a company’s employee count and years of experience) and service portfolio specifications, such as number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed.
Elaborate profiles of antibody discovery service providers. Each company profile features a brief overview of the company, its financial information (if available), antibody discovery service portfolios and an informed future outlook.
A detailed review of the overall landscape of antibody discovery platforms, along with the information on the technology developers such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.
A detailed competitiveness analysis of antibody discovery platforms, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform between 2015 and 2021.
Elaborate profiles of antibody discovery platform providers. Each company profile features a brief overview of the company, its financial information (if available), details on antibody discovery technology / platform(s) offered and an informed future outlook.
An assessment of antibody discovery service and platform providers’ capability in different regions, based on a number of relevant parameters. For platform providers, these parameters include number of technologies offered, number of antibody discovery methods employed, and type of antibody discovered. On the other hand, the service providers have been evaluated based on the type(s) of service offered.
An analysis of the partnerships that have been established in this domain since 2015, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, and other relevant deals.
An analysis of the investments made in this domain, during the period between 2016 and 2021, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, in companies that are engaged in the field of antibody drug discovery.
Detailed profiles on the top five therapeutic antibody products, which have generated the highest revenues. Each profile features a brief overview of the drug, the type of antibody discovery method it employs and the annual historical sales of the product.
A case study on antibody humanization and affinity maturation, including a list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends in this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.
A brief discussion on the imminent opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.
An analysis of the deal structure, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.
One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade. Based on parameters, such as the overall R&D expenditure available to CROs, percentage of R&D expenses incurred in each discovery step, and outsourcing profile, we have provided an informed estimate of the likely evolution of the antibody discovery services market in the mid to long term, for the time period 2021-2035. The report also features the likely distribution of the current and forecasted opportunity within antibody discovery services market across [A] the various steps involved in antibody discovery process (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery methods (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). In addition, for estimating the future market opportunities for platform providers, we have considered the likely licensing deal structures and agreements that are expected to be inked in the foreseen future. The future opportunities within the antibody discovery platforms market has been segmented across key geographical regions (North America, Europe and Asia- Pacific). The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:
Tracey Mullen (Chief Executive Officer, Abveris Antibody)
Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences)
Mark Kubik (Chief Business Officer, AvantGen)
Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
Sanjiban K Banerjee (Director, AbGenics Life Sciences)
Ignacio Pino (Chief Executive Officer and President, CDI Laboratories)
Jeng Her (Chief Executive Officer, AP Biosciences)
Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
Debra Valsamis (Business Development Associate, Antibody Solutions)
Christel Iffland (Vice President, Ligand Pharmaceuticals)
Aaron Sato (former Chief Scientific Officer, LakePharma)
All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
Who are the leading industry players involved in offering services and technologies related to antibody discovery?
What is the relative competitiveness of the players offering services related to antibody discovery, based across different geographies?
What tis the relative competitiveness of the technologies pertaining to antibody discovery across different peer groups?
Which partnership models are commonly adopted by industry stakeholders offering services and technologies related to antibody discovery?
What is the trend for capital investments in the antibody discovery services and platforms market?
How is the current and future market opportunity related to antibody discovery services an platforms, likely to be distributed across key market segments?
CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the antibody discovery services and platform market and its evolution in the short-mid-term and long term.
Chapter 3 provides a general introduction of antibodies featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes on the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.
Chapter 4 features a detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also highlights a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.
Chapter 5 provides a general overview of the current market landscape of more than 80 service providers that are currently active in this domain. It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).
Chapter 6 provides an insightful competitiveness analysis of antibody discovery service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on the year of establishment of the service provider) and service strength (which takes into account the number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed).
Chapter 7 provides detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery services, recent developments and an informed future outlook.
Chapter 8 presents the current market landscape of over 120+ antibody discovery platform providers, including information on their company details such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of 170+ antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.
Chapter 9 provides an insightful competitiveness analysis of antibody discovery platforms. It highlights the leading players in this domain, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform (2015-2021).
Chapter 10 provides detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery technology / platforms to other companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery technology / platforms, recent developments and an informed future outlook
Chapter 11 presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered for platform providers.
Chapter 12 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in this market in the time period between 2015 and 2021 (till November). It includes a brief description of partnership models (such as acquisitions, product development agreements, product integration agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, and service agreements) adopted by the stakeholders.
Chapter 13 presents an analysis of the investments made in this domain during the period 2016-2021 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of discovery in companies that are focused on antibody discovery.
Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of antibody discovery services domain till the year 2035. In order to provide details on the future opportunities, our projections have been segmented on the basis of [A] the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world).
Chapter 15 presents the likely growth of antibody discovery platform market, on the basis of licensing deal structures and agreements signed or planned in the foreseen future. In order to provide details on the future opportunities, the projections have been segmented on the basis of
key geographical regions (North America, Europe and Asia- Pacific).
Chapter 16 provides deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.
Chapter 17 features detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2020). It provides information on top five drugs, namely Humira®, Keytruda®, Stelara®, Opdivo® and Avastin®, their historical sales, and discovery process and methods.
Chapter 18 features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents a list of key players along with the information on their respective location, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models adopted by the players involved in this domain. In addition, chapter provides insights on a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.
Chapter 19 provides an overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry’s evolution over the coming decade.
Chapter 20 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of person name) Tracey Mullen (Chief Executive Officer, Abveris Antibody), Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences), Mark Kubik (Chief Business Officer, AvantGen), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Sanjiban K Banerjee (Director, AbGenics Life Sciences), Ignacio Pino (Chief Executive Officer and President, CDI Laboratories), Jeng Her (Chief Executive Officer, AP Biosciences), Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Aaron Sato (Chief Scientific Officer, LakePharma / Twist Biosciences)
Chapter 21 summarizes the entire report, highlighting the various facts related to contemporary market trend and the likely evolution of the antibody discovery service and platform market.
Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 23 is an appendix, which contains the list of companies and organizations mentioned in the report.
Chapter 23 is an appendix, which contains the list of companies and organizations mentioned in the report.
Read the full report: https://www.reportlinker.com/p06244063/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
David Solomon believes in-office work is crucial to the bank’s success. In a post-pandemic world, will employees agree?
The Tesla CEO now rents in Texas after selling his California homes to Unlimint founder Kirill Evstratov, Chinese billionaire William Ding and others.
WASHINGTON (Reuters) -Ukraine's two leading suppliers of neon, which produce about half the world's supply of the key ingredient for making chips, have halted their operations as Moscow has sharpened its attack on the country, threatening to raise prices and aggravate the semiconductor shortage. Some 45% to 54% of the world's semiconductor-grade neon, critical for the lasers used to make chips, comes from two Ukrainian companies, Ingas and Cryoin, according to Reuters calculations based on figures from the companies and market research firm Techcet. Both firms have shuttered their operations, according to company representatives contacted by Reuters, as Russian troops have escalated their attacks on cities throughout Ukraine, killing civilians and destroying key infrastructure.
Berkshire Hathaway Inc on Friday urged the rejection of four shareholder proposals recommending that it replace Warren Buffett as chairman, report on its plans to handle climate risk and reduce greenhouse gases, and improve diversity. The company, run by Buffett since 1965, also said the 91-year-old received $373,204 in compensation for 2021, down from $380,328 a year earlier, comprising his usual $100,000 salary plus personal and home security. Though Buffett's salary is low for a chief executive officer of a major company, his 16.2% Berkshire stake comprises most of his $117.9 billion net worth, which Forbes magazine said makes him the world's fifth-richest person.
The European Union is planning to cut Russian gas imports. Its target may be aspirational but the political sign looks serious.
Many retirees plan to earn extra income to supplement their retirement spending. But how much can a retired person earn without paying taxes? The answer to this question varies based on your situation. Understanding the tax rules surrounding retiree income can … Continue reading → The post How Much Can a Retired Person Earn Without Paying Taxes? appeared first on SmartAsset Blog.
Employees will receive an extra $2300 per year to compensate.
A corporate exodus from Russia in response to its military invasion of Ukraine has seen more than 300 U.S. and multinational companies sever business ties with the country – and the list seems to be growing by the minute. But even as many flee, a number of big-name firms have remained mum.
Alibaba (BABA) American depository shares closed at 52-week lows following JD.com's (JD) quarterly print, and amid renewed worries over Chinese ADRs delistings off US exchanges.
(Bloomberg) — Much has been written about the hurdles to a U.S.-Venezuela detente that would allow oil from the South American nation to start flowing more freely into international markets. One of them, though, has been overlooked: The presence of a Kremlin-owned company in oil fields all across Venezuela.Most Read from BloombergUkraine Update: U.S. Imposes Sanctions on More Russian EliteBiden Says He’d Fight World War III for NATO But Not for UkraineTech Walls Off Russia Like Never Before, Po
U.S. regulators on Thursday issued final rules eliminating the need for automated vehicle manufacturers to equip fully autonomous vehicles with manual driving controls to meet crash standards. Automakers and tech companies have faced significant hurdles to deploying automated driving system (ADS) vehicles without human controls because of safety standards written decades ago that assume people are in control. Last month, General Motors Co and its self-driving technology unit Cruise petitioned the U.S. National Highway Traffic Safety Administration (NHTSA) for permission to build and deploy a self-driving vehicle without human controls like steering wheels or brake pedals.
The young electric vehicle manufacturer wants to meet demand, while rivals Tesla, Ford and GM are watching for any missteps.
(Bloomberg) — Russia has enough buyers for its oil and gas even as Western nations and their allies impose sanctions in response to the invasion of Ukraine, according to a top Kremlin official.Most Read from BloombergUkraine Open to Russia's Neutrality Demand But Won’t Yield Territory, Aide SaysChina Warns U.S. Over Forming Pacific NATO, Backing TaiwanRussia Devises Plan to Seize Firms Abandoned in Foreigner ExodusRussian Prowess Questioned as Troops Bogged Down in UkraineUkraine and Russia Fai
Gas prices are dramatically rising across the country. Here's what to know about the causes behind this and how long we can expect them to rise.
Real Money investment experts say if Walt Disney Co. can avoid one thing, its next biggest attraction will be 'Profitland.'
A recession may be taking form off in the distance, warns Goldman Sachs.
Tsingshan Holding Group, the world's largest nickel producer, has said that it will be able to tackle a historic short squeeze after gathering sufficient nickel inventory for delivery, and with fresh lifelines from banks. The company has swapped its nickel matte for domestic nickel plate, which will let it close its short position against the metal, state media Securities Daily reported on Thursday citing a reply from Tsingshan. The firm declined to comment on Thursday. Do you have questions abo
(Bloomberg) — Thousands of staff, billions of dollars and three decades of complicated relationships. Some of the world’s largest banks are starting to pull back from Russia, but it’s not going to be easy.Most Read from BloombergUkraine Update: Belarus Says Russia Is Sending ‘Modern’ WeaponsRussia Devises Plan to Seize Firms Abandoned in Foreigner ExodusRussia Bans Export of 200 Products After Suffering Sanctions HitUkraine Update: Russia Targeting Airfields in Western UkraineTech Walls Off Rus
Japanese brands Uniqlo and Japan Tobacco made U-turns and said they were stopping business in Russia, joining the corporate crowd shunning Moscow on Thursday, and Britain escalated sanctions against oligarchs including Chelsea soccer club owner Roman Abramovich. Investment bank Goldman Sachs became the first U.S. bank to quit Russia, and global grain trader Bunge said it had suspended new export business from Russia, although it is still crushing oil seeds for the domestic market.. Russian President Vladimir Putin said that his country would emerge stronger and more independent from Western sanctions, which he said were inevitable.
DocuSign CEO Dan Springer joins Yahoo Finance Live to discuss the company's fourth quarter earnings, work from home trends, and the outlook for growth post-pandemic.